Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.54 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.53 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.53 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.53 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CHKA | P35790 | 5/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3272318 | 1.00 | HDAC6 (0.68) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL14763998 | 1.00 | HDAC6 (0.68) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL3664891 | 0.98 | HDAC6 (0.66) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL1583152 | 0.98 | HDAC6 (0.66) | HDAC6MC4RHRH3LMNACHKA | |
| SCHEMBL16356429 | 0.98 | HDAC6 (0.69) | HDAC6MC4RHRH3LMNACHKA | |
| SCHEMBL65179 | 0.98 | HDAC6 (0.69) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL14763461 | 0.94 | HDAC6 (0.61) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrogen Sulfide SCHEMBL27950422 | 0.92 | HDAC6 (0.62) | HDAC6MC4RHRH3LMNACHKA | |
| SCHEMBL10074441 | 0.89 | HDAC1 (0.62) | HDAC6HRH3LMNAGAATHRB | |
| SCHEMBL15149927 | 0.88 | HDAC6 (0.58) | HDAC6MC4RHRH3LMNACHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106905263-B | A kind of preparation method of 4- (4- methyl-1-piperizinylmethyl) benzoic acid dihydrochloride | 常州沃腾化工科技有限公司 | 2019-06-14 | — | — | CN | claimed |
| CN-103570676-B | Preparation of Imatinib mesylate alpha crystal and pharmaceutical composition thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. (CN) | 2016-03-16 | — | — | CN | claimed |
| WO-2015188243-A1 | PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2015-12-17 | — | — | WO | claimed |
| WO-2013008242-A1 | A PROCESS FOR THE PREPARATION OF HIGHLY PURE 4-(4-METHYL PIPERAZINOMETHYL) BENZOIC ACID DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2013-01-17 | — | — | WO | claimed |
| WO-2012004801-A1 | PROCESS FOR IMATINIB MESYLATE | HETERO RESEARCH FOUNDATION (IN) | 2012-01-12 | — | — | WO | claimed |
| CN-101677955-A | imatinib mesylate | REDDYS LAB LTD DR | 2010-03-24 | — | — | CN | claimed |
| US-12292363-B2 | Method for preparing biological material having excellent light-transmitting property | RIKEN (JP) | 2025-05-06 | — | — | US | disclosed |
| EP-4045494-B1 | SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE | ESCO ASTER PTE LTD (SG) | 2023-10-11 | — | — | EP | disclosed |
| US-11752152-B1 | Pharmaceutical formulations of imatinib and uses thereof | EXVASTAT LTD (GB) | 2023-09-12 | — | — | US | disclosed |
| US-20230065387-A1 | SYNTHESIS OF TYROSINE KINASE INHIBITORS | ESCO ASTER PTE. LTD (SG) | 2023-03-02 | — | — | US | disclosed |
| US-20220381657-A1 | METHOD FOR PREPARING BIOLOGICAL MATERIAL HAVING EXCELLENT LIGHT-TRANSMITTING PROPERTY | RIKEN (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-4045494-A1 | SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE | Esco Aster Pte. Ltd. (SG) | 2022-08-24 | — | — | EP | disclosed |
| CN-114585615-A | Synthesis of 6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine | 新加坡艺思高艾斯特生物科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-1724264-A1 | NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2005-09-22 | — | — | US | disclosed |
| EP-1470120-A1 | N-OXYDE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062220-A1 | N-OXYDE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2003-07-31 | — | — | WO | disclosed |
| EP-0208404-B1 | BENZOTHIAZINE DIOXIDE DERIVATIVES | PFIZER INC. (US) | 1990-08-29 | — | — | EP | disclosed |
| EP-0208404-A2 | Benzothiazine dioxide derivatives | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| US-4623486-A | [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752152-B1 | Pharmaceutical formulations of imatinib and uses thereof | ABL1, JAK2, ABL2 | HDAC6 615/4885HRH3 3411/4885GAA 317/4885 |
| US-20050209452-A1 | Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | MKI67, CDK4, NME2 | HDAC6 1023/4885HRH3 1339/4885GAA 3671/4885 |
| US-20230065387-A1 | SYNTHESIS OF TYROSINE KINASE INHIBITORS | ABL1, ROS1, ABL2 | HDAC6 2448/4885HRH3 3697/4885GAA 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.